Mixed allogeneic lymphocyte response has activated considering T lymphocytes and elicit type 1 cytokines which induced antitumor immunity. Using TC-1 cancer model, we demonstrated the response of inactivated allogeneic leukocytes infusion (ALI) to generate antitumor immune response. In TC-1 tumor model, ALI induced a delayed cancer development and a prolonged survival. Our study illustrated that ALI might elicit strong antitumor immune response. The method strategy would be easy and efficient strategy in tumor immunotherapy.
Introduction
Allogeneic transplantation was being used as a successful method for tumor therapy. Under the clear illustration of transplantation immunology, it is realized that alloantigen was an immunostimulator to elicit an immune effect in host vs. graft (HVG) or graft vs. host (GVH) 1]. In the GVH and HVG biology, there were similar mechanisms to antitumor effects, including cytolysis, antigen-presenting cells (APCs) revitalite, and IFN-γsecreting type T cells. So theses mechanisms might be used in the tumor therapy. Graft rejection represents an immune effect which was persistent and intensity. In the allogeneic transplantation, the 
Materials and methods

Mice and cell lines
Inbred female C57BL/6 (B6, H-2) and BALB/c mice (8-10 weeks) were purchased from the Experimental Animal
Institute of Peking Union Medical College. All protocols were in accordance with recommendations for the proper care of laboratory animals.
TC-1 tumor cells derived from C57BL/6 mice co-transformed with HPV-16 E6, E7 and c-Haras oncogenes were provided by Dr. T.C. Wu from Johns Hopkins University.
Cell vaccine preparation
Murine splenocytes were separated from freshly spleens of BALB/c mice. For inactivating splenocytes, 25 mg/mL mitomycin C (MMC) were taken into the cell suspension in a concentration of 1×10 7 cells/mL. And the cells were incubated for 60 min. At last the cell were washed with phosphate-buffered saline (PBS) and resuspended. 
Cancer therapeutic protocol
Statistical analysis
Student's t-test was used to compare means between the 2 groups. Logrank test were analyzed in the survival data.
Differences were considered to be significant when p < 0.05. Statistical analysis was performed using commercially available software (SPSS 11.0). ( Fig 1A,P<0.05 ).
As shown in Figure 1B and Table 1, 
Discussion
The antitumor response of allogeneic leukocytes was illustrated in previous study [5, 6] . All the previous studies were depends on the graft-versus-tumor or graft-versus-leukemia effect which mediated by competent donor cells [7] . In our study, we illustrated that an antitumor immunity could been elicited by an inactivated MHC mismatched allogeneic leukocytes.
ALI might elicit antitumor immunity in 3 methos. First, the anergic and tumor-specific T cells might be elicited in the polyclonal allogeneic response. Second, the CD4+T-cell direct allorecognition response to MHC-II molecules could afford T-cell help for the self-restricted reaction to cancer peptides. Finally, the inherent immune system might induce an immunostimulatory environment [8, 9] .
The reports demonstrated that allogeneic response between HLA-unmatched people elicit a markedly raise of type 1 cytokines such as IFN-γ.10 IFN-γwas a key factor p in promoting host inherent and acquired immune reaction.
Other studies have also showed that allogeneic response induce maturation and migration of DCs [10] .
The another novel aspect of our study was related to a reversal of lymphopenia in a cancer bearing host. Our results showed that inactivated ALI could inhibit the cancer growth by inducing type-1 cytokine storm. These cytokines could induce both nonspecific and specific antitumor immune effect. In conclusion, it is sensible to desire the therapeutic modality might be an attractive method in cancer therapy.
